(Q80146976)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Ulrike Heider

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Martin Kaiser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Christian Müller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Christian Jakob

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Ivana Zavrski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Carsten-Oliver Schulz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Claudia Fleissner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Monica Hecht

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Orhan Sezer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

233-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Fracture risk with multiple myeloma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Immunocytochemistry reveals RANKL expression of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Proteasome: an emerging target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Regulation of beta-catenin signaling and maintenance of chondrocyte differentiation by ubiquitin-independent proteasomal degradation of alpha-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00692.X

10.1111/J.1600-0609.2006.00692.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16923110%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference